VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a global leader in the development of non-human primate (NHP) models for clinical research applications, have signed a strategic partnership that will establish the world’s first primate gene therapy R&D center. The center will build advanced vector screening and optimization platforms to provide unique CRO services to the rapidly growing gene and cell therapy industry. VectorBuilder brings cutting-edge gene delivery technologies to the company, while Landau will provide expertise in building NHP models using Macaca fascicularis (crab-eating macaque) and Macaca mulatta (rhesus macaque). Specifically, the center will combine directed molecular evolution with in vivo screening in NHPs, resulting in the next generation of gene delivery vectors suitable for human clinical applications. In particular, the center will focus on improving the specificity of tissue targeting and expression pattern of vectors, as well as reducing toxicity and immunogenicity.
“Non-human primates share high degrees of similarities with humans in terms of anatomy, genomic function, immunity and physiology. They are therefore ideal animal models for the screening and optimization of gene therapy vectors, ”said VectorBuilder Chief Scientist Dr. Bruce Lahn. “We believe that by working closely with Landau, we will be able to create a leading CRO capable of providing these vital services to the gene and cell therapy community. “
Landau President Mr. Lei Fan added, “VectorBuilder is a global pioneer in gene delivery, and we are very happy to be partnering with the company. The launch of this center marks a major milestone in genetic medicine, and we hope this will allow us to partner with other leading biopharmaceutical companies around the world to develop the next generation of gene therapy drugs.
About VectorBuilder Inc.
VectorBuilder is a rapidly growing biotechnology company specializing in advanced genetic engineering solutions for research and medicine. In particular, VectorBuilder has established itself as the global leader in a range of products and services related to gene delivery, including vector design and optimization, vector cloning, virus packaging, construction and screening of libraries, generation of stable cell lines and GMP manufacture of clinical products. -grade plasmids, mRNAs, proteins and viruses. One of the strengths of VectorBuilder’s innovative solutions is its revolutionary online platform for designing and ordering custom vectors, available at https://www.vectorbuilder.com. This award-winning platform has become very popular with researchers around the world and has become an industry standard for its rich functionality, extensive experimental validations, and easy-to-use graphical interface. By leveraging the popularity of this platform, VectorBuilder has built a comprehensive portfolio of offerings covering virtually all gene delivery needs, from the lab to the bedside.
About Landau Biotechnology Co.
Landau is one of the first organizations in China to produce NHPs on a large scale for biomedical research. It is also a world leader in the development of NHP models for various human diseases and clinical applications. Over the past 40 years, Landau has provided a wide range of services based on NHP models, including pharmacodynamic research, drug metabolism research, early drug detection, surgeries, and clinical experiments. ethology, radiology and ophthalmology for a large number of research institutes and biopharmaceuticals. companies around the world.